key: cord-1026575-9990qwnn
authors: Hou, Hongyan; Chen, Jun; Wang, Yueqin; Lu, Yanjun; Zhu, Yaowu; Zhang, Bo; Wang, Feng; Mao, Lie; Tang, Yi-Wei; Hu, Bicheng; Ren, Yi; Sun, Ziyong
title: Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Assay for the Detection of SARS-CoV-2 in Oropharyngeal Swab Specimens
date: 2020-07-23
journal: J Clin Microbiol
DOI: 10.1128/jcm.01288-20
sha: de2356c8e4e2d88d4936703eec59a60b4a81d484
doc_id: 1026575
cord_uid: 9990qwnn

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a global health concern that has spread worldwide since December 2019 (1-4).….

methods. The positive percent agreement of the Xpert assay was 96.1% (95% confidence interval [CI], 91.3 to 98.4%), negative percent agreement was 96.2% (95% CI, 90.9 to 98.6%), and the Kappa statistic was 0.92 (95% CI, 0.88 to 0.97) ( Table 1) . Three additional mixed samples with low, middle, and high threshold cycle (C T ) levels for SARS-CoV-2 were run by three different staff members on three different days in triplicate using one machine and one lot number of reagents. The coefficients of variation (CVs) of the Xpert assay were 0.86%, 0.73%, and 0.7% for the N2 gene and 0.84%, 0.7%, and 1.95% for the E gene in mixed samples with low, middle, and high C T values, respectively. The Xpert assay showed intratest CVs from 0.2 to 1.17% and 0.21 to 1.27% for the detection of N2 and E genes, respectively.

The upper respiratory samples for RT-PCR tests of SARS-CoV-2 virus included OPS and NPS. Although the positive rates of NPS and sputum were reported as higher than those for OPS, OPS specimens have been more widely used in China (5, 10) . The OPS specimens were recommended to be collected for real-time RT-PCR assay by the first to fifth editions of the "Guideline of diagnosis and treatment for COVID-19" by the Chinese National Health Commission. Moreover, a swab might have a hard handle, which may cause bleeding when it is inserted into the nostril. This resulted in the dominant use of OPS as upper respiratory specimens in the early COVID-19 outbreak in China. This is, to our knowledge, the first clinical study assessing the Cepheid Xpert Xpress SARS-CoV-2 assay in mainland China. Overall, the Xpert assay demonstrated high positive percent agreement (PPA) and negative percent agreement (NPA) for the detection of SARS-CoV-2 compared with results of the NMPA-approved real-time RT-PCR method. The assay is easy to use and provides rapid, accurate, and reproducible results for detection of SARS-CoV-2 in OPS at the point of care. 

A distinct name is needed for the new coronavirus

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

COVID-19: a promising cure for the global panic

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in

Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19)

A new coronavirus associated with human respiratory disease in China

The laboratory diagnosis of COVID-19 infection: current issues and challenges

The detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 assays

Multicenter evaluation of the Cepheid Xpert Xpress SARS-CoV-2 test

Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously

Laboratory diagnosis of emerging human coronavirus infections-the state of the art

This study was funded in part by the National Mega Project on Major Infectious Disease Prevention (grant 2017ZX10103005-007) and by a Cepheid Investigator-Initiated Study award (Cepheid-IIS-2020-005).We thank Charles Stratton for critically reviewing the manuscript.Y.-W.T. is an employee of Cepheid, the commercial manufacturer of the Xpert Xpress SARS-CoV-2 test. The other authors declare no competing interests.